Gallium ga 68 dotatate Pregnancy and Breastfeeding Warnings
Gallium ga 68 dotatate is also known as: Netspot
Gallium ga 68 dotatate Pregnancy Warnings
There are no controlled data in human pregnancy. The estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.
Safety has not been established during pregnancy.
Risk Summary:
-There are no studies in pregnant women to inform any drug-associated risks; however, all radiopharmaceuticals, including this drug have the potential to cause fetal harm.
Gallium ga 68 dotatate Breastfeeding Warnings
A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comment: Interrupt breastfeeding and pump and discard breast milk for 12 hours after administration of this drug to minimize radiation exposure to a breastfed infant.
See also
References for pregnancy information
- "Product Information. Netspot (dotatate)." Advanced Accelerator Applications (2016):
References for breastfeeding information
- "Product Information. Netspot (dotatate)." Advanced Accelerator Applications (2016):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.